45 CFR § 180 compliance
F · 50
This hospital published little of what § 180 requires.
●Machine-readable file published
●Gross / standard charges
○Discounted cash price
○Payer-specific negotiated rates
○Min / max negotiated charges
●Free, public, no login required
Procedures listed
3,130
Insurances with rates
0
CPT / HCPCS codes
1,263
Source MRF
Most expensive procedures (gross)
| Code | Description | Gross | Cash | Min payer | Max payer | # insurers |
|---|---|---|---|---|---|---|
| J9043 | CABAZITAXEL (Jevtana) 60mg INJ | $80,186 | — | — | — | 0 |
| J9144 | DARATUMUMAB HYAL(DARZALEX FASPRO) 1800MG | $55,705 | — | — | — | 0 |
| J1628 | TREMFYA (guselkumab) 200mg inj | $52,250 | — | — | — | 0 |
| J2993 | RETEPLASE (RETAVASE) 10.4U/18.1MG | $41,420 | — | — | — | 0 |
| J9308 | RAMUCIRUMAB (CYRAMZA) 500MG VIAL | $38,909 | — | — | — | 0 |
| J9301 | GAZYVA (OBINUTUZUMAB) 1000MG VIAL | $38,835 | — | — | — | 0 |
| J3101 | TENECTEPLASE (TNKASE) 50MG KIT | $36,333 | — | — | — | 0 |
| J9306 | PERTUZUMAB (PERJETA) 420MG/14ML | $31,093 | — | — | — | 0 |
| C1767 | LVL I IMPLANT NEUROSTIMULATOR ELECTOD | $30,644 | — | — | — | 0 |
| 2051189 | NF-Nystatin Powder | $27,718 | — | — | — | 0 |
| J9228 | IPILIMUMAB (YERVOY) 200MG/40ML INJ SOLN | $24,570 | — | — | — | 0 |
| J2506 | PEGFILGRASTIM (NEULASTA) 6MG INJ | $22,867 | — | — | — | 0 |
| J1930 | LANREOTIDE SUBQ SOLN 120MG/0.5ML | $21,636 | — | — | — | 0 |
| J0840 | ANTIVENIN POLY IMMUNE (CROFAB) 1 VL | $21,572 | — | — | — | 0 |
| J9354 | ADO-TRASTUZUMAB 100MG VIAL | $21,175 | — | — | — | 0 |
| J9035 | BEVACIZUMAB (AVASTIN) 400MG | $18,072 | — | — | — | 0 |
| J9311 | RITUXIMAB (RITUXAN HYCELA) 1400 MG VIAL | $17,264 | — | — | — | 0 |
| J9355 | TRASTUZUMAB (HERCEPTIN) 440 MG VIAL | $16,652 | — | — | — | 0 |
| 2051774 | NF-Humira Subcutaneous Kit | $16,628 | — | — | — | 0 |
| J9271 | PEMBROLIZUMAB (KEYTRUDA) 50 MG VIAL | $16,488 | — | — | — | 0 |
| J9305 | PEMETREXED (ALIMTA) 500 MG | $16,028 | — | — | — | 0 |
| J9312 | RITUXIMAB (RITUXAN) 500 MG VIAL | $14,259 | — | — | — | 0 |
| J3240 | THYROTROPIN POWDER FOR INJ 1.1MG | $13,962 | — | — | — | 0 |
| J2353 | OCTREOTIDE (SANDOSTATIN LAR )30 MG | $13,251 | — | — | — | 0 |
| J3110 | TERIPARATIDE (FORTEO) 20MCG PEN | $12,401 | — | — | — | 0 |
| J1162 | DIG IMMUNE FAB (DIGIBIND) 40MG/VIAL | $11,396 | — | — | — | 0 |
| C1897 | NEUROSTIMULATOR IMPLANT PERC. | $10,087 | — | — | — | 0 |
| C1778 | LVL II IMPLANT NEUROSTIMULATOR ELECTOD | $10,087 | — | — | — | 0 |
| J9207 | IXABEPILONE (IXEMPRA) 15 MG | $9,519 | — | — | — | 0 |
| J9330 | TEMSIROLIMUS (TORISEL) 25MG INJ | $9,311 | — | — | — | 0 |
| Q2050 | DOXORUBICIN LIPOSOME (DOXIL) 20 MG | $9,241 | — | — | — | 0 |
| J0894 | DECITABINE (DACOGEN) 50MG VIAL | $9,203 | — | — | — | 0 |
| J2997 | ALTEPLASE (ACTIVASE) 50MG VIAL | $9,086 | — | — | — | 0 |
| 2049444 | NF-Nplate SubQ Powder for Solution 250MC | $8,956 | — | — | — | 0 |
| Q9968 | ISOSULFAN BLUE 1% 50MG/5ML | $8,910 | — | — | — | 0 |
| 77301 | IMRT TREATMENT PLAN | $8,700 | — | — | — | 0 |
| 1080105 | VASCULAR MAJOR 1ST HOUR | $8,558 | — | — | — | 0 |
| J9303 | PANITUMUMAB (VECTIBIX) 20 MG | $8,496 | — | — | — | 0 |
| Q5108 | PEGFILGRASTIN (FULPHILA) 6MG INJ | $8,481 | — | — | — | 0 |
| J2802 | ROMIPLOSTIM (NPLATE) 250MCG | $8,298 | — | — | — | 0 |
| 2051240 | NF-Forteo Subcutaneous Solution 250MCG/1 | $8,117 | — | — | — | 0 |
| J9299 | OPDIVO (NIVOLUMAB) 40MG/4ML INJ SOLN | $8,048 | — | — | — | 0 |
| 2050785 | NF-Forteo Subcutaneous Solution 250MCG/1 | $7,805 | — | — | — | 0 |
| J9041 | BORTEZOMIB (VELCADE) 3.5 MG INJ | $7,782 | — | — | — | 0 |
| 1430727 | PROCEDURE CATEGORY 3 | $7,748 | — | — | — | 0 |
| 1080362 | ORTHO MAJOR 1ST HOUR | $7,655 | — | — | — | 0 |
| 1080101 | MAJOR PROCEDURE 1ST HOUR | $7,367 | — | — | — | 0 |
| J1459 | IVIG 10GM (PRIVIGEN) | $7,363 | — | — | — | 0 |
| J0883 | ARGATROBAN 250MG INJ | $7,317 | — | — | — | 0 |
| 1080107 | VASCULAR MINOR 1ST HOUR | $7,103 | — | — | — | 0 |
Showing top 50 of 3,130 priced procedures, sorted by gross charge.
Data straight from this hospital's federally-mandated machine-readable file (45 CFR § 180). The compliance grade reflects how completely the hospital published the six required data elements, not the quality of care.